Prognostic stratification in patients who received hormonal therapy for prostate-specific antigen recurrence after radical prostatectomy.
The present study was undertaken to investigate the predictors in patients who received hormonal therapy (HT) for prostate-specific antigen recurrence (PSAR) after surgery. Predictors for the progression-free survival were assessed in 55 patients who received HT for PSAR after surgery. In multivariate analysis, primary Gleason grade > or =4 and PSA doubling time (PSA-DT) <6 months were independent predictors. The patients were stratified into low-risk group (Gleason grade <4 and PSA-DT > or =6), high-risk group (Gleason grade > or =4 and PSA-DT <6) and intermediate-risk group (all others). In the intermediate- and high-risk groups, progression-free survival rate was significantly higher in patients with PSA level <2 than in those with PSA level > or =2 at the initiation of HT. Primary Gleason grade > or =4 and PSA-DT <6 months are independent predictors. Patients in the intermediate- and high-risk groups may benefit from early HT for PSAR after surgery.
Ide
Hiroki
H
Department of Urology, Keio University School of Medicine, Tokyo, Japan.
Nakashima
Jun
J
Kono
Hidaka
H
Kikuchi
Eiji
E
Nagata
Hirohiko
H
Miyajima
Akira
A
Nakagawa
Ken
K
Oya
Mototsugu
M
D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use*; D018572:Disease-Free Survival; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology / Q000601:surgery; D012008:Recurrence; D013534:Survival
D000726:Androgen Antagonists; D017430:Prostate-Specific Antigen